E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic hepatitis C-infected patients |
|
E.1.1.1 | Medical condition in easily understood language |
Hepatitis C is an infectious disease affecting the liver, caused by hepatitis C virus |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10019744 |
E.1.2 | Term | Hepatitis C |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- Evaluate safety and tolerability of 12 weeks dosing regimen containing TMC647055 once daily (q.d.), TMC435 q.d., and RTV q.d., at selected doses with and without RBV (2 daily doses) in chronic HCV genotype 1 infected (cHCV GT1) patients
- Evaluate efficacy of 12 weeks combination therapy of TMC647055 q.d., TMC435 q.d. and RTV q.d., at selected doses with RBV (2 daily doses) in treatment-naïve/prior relapser (TN/PR) cHCV GT1 patients
- Evaluate efficacy of 12 weeks combination therapy of TMC647055 q.d., TMC435 q.d. and RTV q.d., at selected doses in TN/PR cHCV genotype-1b infected patients
- Evaluate plasma PK of TMC647055, TMC435 and RTV of 12 weeks dosing regimen containing TMC647055 q.d., TMC435 q.d., RTV q.d., at selected doses with and without RBV (2 daily doses)
- Evaluate safety, tolerability, PK and efficacy of 12 weeks combination therapy of TMC435 q.d., TMC647055 q.d., RTV q.d. and GSK2336805 q.d. without RBV, in a population of TN/PR cHCV GT1 patients |
|
E.2.2 | Secondary objectives of the trial |
- To explore the relationship between TMC647055, TMC435, RTV and/or GSK2336805 exposure and efficacy and/or safety. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Documented chronic genotype 1a or genotype 1b hepatitis C virus (HCV) infection with HCV RNA level >100,000 IU/mL at screening
- Treatment-naive, documented prior relapse or null responder to previous treatment regimens and has stopped treatment at least 3 months before screening
- Liver biopsy within 3 years before the screening visit or elastography results availabe prior to first study drug dosing
- Medically stable based on physical examination, medical history, vital signs, and electrocardiogram performed at screening
- Body mass index of 18.0 to 32.0 kg/m2 and body weight >50 kg
|
|
E.4 | Principal exclusion criteria |
-Evidence of liver cirrhosis by liver biopsy or the presence of esophageal varices or a transient elastography result of >14.6 kPa within 2 years prior to first dosing
- Evidence of decompensated liver disease defined as prior history or current evidence of ascites, hepatic encephalopathy, bleeding oesopaghal or gastric varices
- Evidence of any significant liver disease in addition to hepatitis C (including but not limited to hepatitis B, drug- or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson’s disease, non-alcoholic steatohepatitis, or primary biliary cirrhosis)
- Receiving or has received any HCV-specific direct antiviral agent (HCV protease inhibitors, HCV nucleoside polymerase inhibitors, HCV non-nucleoside polymerase inhibitors, HCV NS5a inhibitors or any other HCV inhibitor targeting an HCV protein or a target involved in the HCV replication cycle
- Has participated in another clinical trial with an investigational drug, vaccine or device within 90 days prior to screening
- Co-infected with human immunovirus (HIV)-1 or HIV-2, with non-genotype 1a/1b HCV, or hepatitis A or B virus infection
- Any cardiac disease at screening, or any active clinical significant disease, or medical history or physical examination findings during screening that, in the investigator’s opinion, could compromise the outcome of the trial
- History or evidence of current abuse of alcohol (5 glasses/day during 5 years), barbiturate, amphetamine, recreational or narcotic drug use, which in the investigator’s opinion would compromise subject’s safety and/or compliance with the study procedures
- Positive urine drug (with exclusion of methadone or equivalent) test at study screening
- Protocol-specified laboratory values
- Liver transplant, or any organ/tissue transplant
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Proportion of subjects with a sustained virologic response (SVR) 12 weeks after the actual end of treatment. SVR12 is defined as undetectable HCV RNA at the actual end of treatment and HCV RNA < 25 IU/mL at 12 weeks after the actual end of treatment
- Proportion of subjects with adverse events and SAEs - abnormal changes in safety related laboratory values - abnormal changes in vital signs and physical examination - abnormal electrocardiogram (ECG)
[Timeframe = up to 24 weeks after actual end of treatment]
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
week 24 for the 12 week direct antiviral treatment duration |
|
E.5.2 | Secondary end point(s) |
- Proportion of subjects with a sustained virologic response (SVR) 12 weeks after the actual end of treatment.
[Timeframe: 12 weeks after actual end of treatment]
- Proportion of subjects with a sustained virologic response (SVR) 4 weeks after the actual end of treatment.
[Timeframe: 4 weeks after actual end of treatment]
- Proportion of subjects with a sustained virologic response (SVR) 24 weeks after the actual end of treatment.
[Timeframe: 24 weeks after actual end of treatment]
- HCV RNA levels over time
[Time frame = up to 24 weeks after actual end of treatment]
- Proportion of subjects with undetectable hepatitis C virus (HCV) RNA (<25 IU/mL undetectable) and/or HCV RNA levels <25 IU/mL at all time points
[Time frame = up to 24 weeks after actual end of treatment]
- Proportion of subjects with on-treatment virologic failure
[Time frame = up to actual end of treatment]
- Proportion of subjects with viral relapse
[Time frame = up to 24 weeks after actual end of treatment]
- Proportion of subjects with presence of HCV variants associated with reduced susceptibility to investigational treatment
[Time frame = up to 24 weeks after actual end of treatment]
- PK parameters of TMC435, TMC647055 and RTV and GSK2336805 at Week 4 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 7 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 11 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |